On Wednesday March 9, 2011 The (FDA) U.S. Food and Drug Administration approved the use of Benlysta for the treatment of persons receiving standard therapy for lupus. (SLE) systemic erythematosus commonly called lupus is an autoimmune disease.
With lupus the B lymphocytes a type of white blood cell turn the body's immune defenses against the body's own cells. The B lymphocytes are part of the body's immune system response to perceived infection.
The approved drug Benlysta inhibits the maturation of the B lymphocyte cells. The drug targets a protein that may reduce the number of abnormal B cells and disrupt the progression of the lupus disease process.
Benlysta is prescribed with other treatments to help ease the painful symptoms lupus can cause.
Home Care Path www.homecarepath.com coordinates elder home care assistants to help seniors with chores. Serving South Central Wisconsin.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment